Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults
PCV13 vaccination protected adults ≥65 years against IPD due to PCV13 serotypes. Continued surveillance will be critical in the ≥65-year-old population to assess the impact of higher valent PCVs on IPD serotype distribution, including individual serotypes such as serotype 3.
Authors
- Lindsay R. Grant (ORCID: https://orcid.org/0000-0002-4538-6424)
- Amber Hsiao (ORCID: https://orcid.org/0000-0003-2295-0886)
- Nicola P. Klein (ORCID: https://orcid.org/0000-0003-1777-4814)
- Julius Timbol
- John Hansen (ORCID: https://orcid.org/0000-0001-7891-2673)
- Jose A Suaya
- Bradford D. Gessner (ORCID: https://orcid.org/0000-0002-6216-7194)
- Ronika Alexander-Parrish (ORCID: https://orcid.org/0000-0003-0932-7467)
- Ned Lewis
Institutions
- Kaiser Permanente (US)
- Pfizer (United States) (US)
- Kaiser Permanente Oakland Medical Center (US)
- Brandeis University (US)
Publication Details
- Journal
- Vaccine
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126543
- Citations
- 10
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 3.87